결핵 진료지침
58. Lee H, Jeong BH, Park HY, Jeon K, Huh HJ, Lee NY. Treatment outcomes with fluoroquinolone-containing regimens for isoniazid-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 2016;60:471-7.
59. Báez-Saldaña R, Delgado-Sánchez S, García-García L, Cruz-Hervert LP, Montesinos-Castillo M, Ferreyra-Reyes L, et al. Isoniazid mono-resistant tuberculosis: impact on treatment outcome and survival of pulmonary tuberculosis patients in Southern Mexico 1995-2010. PLoS One 2016;11:e0168955.
60. Villegas L, Otero L, Sterling TR, Huaman MA, Van der Stuyft P, Gotuzzo E, et al. Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru. PLoS One 2016;11:e0152933.
61. Romanowski K, Chiang LY, Roth DZ, Krajden M, Tang P, Cook VJ, et al. Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada. BMC Infect Dis 2017;17:604.
62. Garcia GJC, Guizado VAA, Ticona AM, Alarcon E, Heldal E, Moore DAJ. Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014. PLoS One 2018;13:e0206658.
63. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med 2018;6:265-75.
64. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/ IDSA clinical practice guideline. Am J Respir Crit Care Med 2019;200: e93-e142.
65. Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45:1001-7.
66. Ramachandran G, Hemanth Kumar AK, Srinivasan R, Geetharani A,
<PAGE>138
### Ⅲ. 약제내성결핵의 치료